Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, AltPep Corp is raising $74,999,996.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Valerie Daggett played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AltPep Corp
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach. Our lead program aims to identify Alzheimers Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.

To learn more about AltPep Corp, visit http://www.altpep.com/

Contact:
Valerie Daggett, Chief Executive Officer
425-269-2862
valerie@altpep.com
https://www.linkedin.com/in/valerie-daggett-83690b98/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved